Qiagen N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
28 jul 2016 - 22:05
Statutaire naam
Qiagen N.V.
Titel
QIAGEN reports results for second quarter of 2016; increased commitment to return $300 million of capital to shareholders by end-2017
Bericht
• Q2 2016 results show QIAGEN delivering on goals for acceleration during the year
o Net sales of $334.4 million (+5% actual, +6% constant exchange rates, CER); EPS of $0.09; adjusted EPS of $0.24 ($0.24 CER)
o 8% CER sales growth excluding impact from lower U.S. HPV test sales
o Free cash flow up 75% to $77.6 million
• Sample to Insight portfolio transformation gaining momentum on improving trends among customers in Life Sciences and Molecular Diagnostics
• QIAGEN on track for continued acceleration in H2 2016 and achieving targets for full-year 2016 growth in net sales and adjusted EPS
• Increased commitment to return $300 million to shareholders by end of 2017
Datum laatste update: 19 maart 2025